Inspire diquafosol submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Inspire submits an NDA for its dry eye therapy diquafosol (2% preservative-free solution) June 20 based on two Phase II and two Phase III trials in over 1,200 patients. The firm is touting diquafosol's mechanism of action. "By stimulating P2Y2 receptors located on the ocular surface and inner lining of the eyelid, diquafosol enhances the secretion of water, salt, mucin and lipids," Inspire said. NDA submission triggers a milestone payment from Inspire's partner Allerga